# Miklos Rohla

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 15 papers | 266 citations | 1040056 9 h-index | 996975 15 g-index |
| 16 all docs | 16 docs citations | 16 times ranked | 558 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open, 2019, 9, e022478. | 1.9 | 50 |
| 2 | Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. American Journal of Medicine, 2019, 132, 749-757.e5. | 1.5 | 48 |
| 3 | Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. International Journal of Cardiology, 2018, 265, 141-147. | 1.7 | 38 |
| 4 | Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease. International Journal of Cardiology, 2015, 184, 108-114. | 1.7 | 24 |
| 5 | Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. International Journal of Cardiology, 2018, 270, 160-166. | 1.7 | 24 |
| 6 | Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 191-197. | 3.0 | 15 |
| 7 | Awareness, treatment, and control of hypertension in Austria. Journal of Hypertension, 2016, 34, 1432-1440. | 0.5 | 13 |
| 8 | Metabolic syndrome, inflammation and atherothrombosis. Hamostaseologie, 2013, 33, 283-294. | 1.9 | 13 |
| 9 | Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. American Heart Journal, 2020, 228, 98-108. | 2.7 | 11 |
| 10 | Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. International Journal of Cardiology, 2020, 318, 67-73. | 1.7 | 11 |
| 11 | Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006852. | 2.2 | 11 |
| 12 | Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. Internal and Emergency Medicine, 2021, 16, 591-599. | 2.0 | 4 |
| 13 | Lowering blood pressure in primary care in Vienna (LOW-BP-VIENNA). Wiener Klinische Wochenschrift, 2018, 130, 698-706. | 1.9 | 2 |
| 14 | Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization. Wiener Klinische Wochenschrift, 2016, 128, 906-915. | 1.9 | 1 |
| 15 | Stroke and recurrent left atrial appendage thrombus in a patient with atrial fibrillation under old and new oral anticoagulants: A case report. Thrombosis and Haemostasis, 2014, 111, 375-378. | 3.4 | 0 |